Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia
| Autor: | András Bors, Emma Ádám, Tamás Masszi, Attila Tordai, Éva Karászi, Zoltán Mátrai, Anikó Szilvási, Gabriella Halm, András Kozma, Hajnalka Andrikovics |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Multivariate analysis Chronic lymphocytic leukemia CD38 Biology Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Biomarkers Tumor Humans RNA Messenger Male gender Aged Aged 80 and over Chromosome Aberrations Lipoprotein lipase General Medicine Middle Aged medicine.disease Prognosis Cytogenetic Aberrations Leukemia Lymphocytic Chronic B-Cell Peripheral blood Lipoprotein Lipase Real-time polymerase chain reaction 030220 oncology & carcinogenesis Immunology Mutation Female 030215 immunology |
| Zdroj: | Pathology oncology research : POR. 23(1) |
| ISSN: | 1532-2807 |
| Popis: | The marked clinical heterogeneity of CLL makes early prognosis assessment important. Lipoprotein lipase (LPL) has been shown to confer adverse prognosis in CLL, recent data indicating it might also contribute to CLL cell survival and metabolism. We determined LPL mRNA expression in unselected peripheral blood of 84 CLL patients by RT PCR. Results were correlated with other prognostic markers and outcome. 30/84 (40 %) of cases were LPL positive based on the cutoff established by ROC analysis. In LPL positive patients significantly shorter median survival (136 vs 258 months, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink